单位：[1]Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-JapanFriendship Hospital, Beijing, China[3]China-Japan Friendship Hospital, National Clinical Research Center for RespiratoryDiseases, Clinical Center for Pulmonary Infections, Capital Medical University, Beijing, China[4]Laboratory of ClinicalMicrobiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan FriendshipHospital, Beijing, China[5]Tsinghua University-Peking University Joint Center for Life Sciences, Tsinghua University, Beijing,China
Colistin-resistant (Col-R) bacteria are steadily increasing, and are extremely difficult to treat. New drugs or therapies are urgently needed to treat infections caused by these pathogens. Combination therapy with colistin and other old drugs, is an important way to restore the activity of colistin. This study aimed to investigate the activity of colistin in combination with the anti-rheumatic drug auranofin against Col-R Gram-negative bacteria. The results of checkerboard analysis demonstrated that auranofin synergized with colistin against Col-R Gram-negative bacteria. Time-kill assays showed significant synergistic antimicrobial activity of colistin combined with auranofin. Electron microscopy revealed that the combination resulted in more cellular structural alterations compared to each drug alone. Auranofin enhanced the therapeutic effectiveness of colistin in mouse peritoneal infection models. These results suggested that the combination of colistin and auranofin might be a potential alternative for the treatment of Col-R Gram-negative bacterial infections.
基金：
Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81970010/H0104]; National Key Research and Development Program of China [2018YFC1200102]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2017ZX10103004]; CAMS Innovation Fund for Medical Sciences [CIFMS 2018-I2M-1-003]
第一作者单位：[1]Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-JapanFriendship Hospital, Beijing, China
通讯作者：
通讯机构：[1]Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-JapanFriendship Hospital, Beijing, China[3]China-Japan Friendship Hospital, National Clinical Research Center for RespiratoryDiseases, Clinical Center for Pulmonary Infections, Capital Medical University, Beijing, China[4]Laboratory of ClinicalMicrobiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan FriendshipHospital, Beijing, China[5]Tsinghua University-Peking University Joint Center for Life Sciences, Tsinghua University, Beijing,China
推荐引用方式(GB/T 7714)：
Feng Xiaoxuan,Liu Shuai,Wang Yang,et al.Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria[J].FRONTIERS in MICROBIOLOGY.2021,12:doi:10.3389/fmicb.2021.676414.
APA：
Feng, Xiaoxuan,Liu, Shuai,Wang, Yang,Zhang, Yulin,Sun, Lingxiao...&Cao, Bin.(2021).Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria.FRONTIERS in MICROBIOLOGY,12,
MLA：
Feng, Xiaoxuan,et al."Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria".FRONTIERS in MICROBIOLOGY 12.(2021)
生物